Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CStone Pharmaceuticals Reports First Half 2019 Financial Results 2019-08-15 15:31
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study 2019-08-13 12:21
CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park 2019-08-07 14:47
CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML 2019-07-22 12:17
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST 2019-07-10 10:23
CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib 2019-06-10 09:30
CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC 2019-06-05 19:56
CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML 2019-06-03 11:45
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint 2019-05-23 18:36
CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy 2019-05-02 11:05
First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma 2019-04-16 16:58
CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors 2019-04-15 14:32
CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR 2019-04-04 23:44
CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board 2019-03-25 15:14
CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009) 2019-03-21 21:32
CStone received IND approval in China for HDAC6 inhibitor CS3003 2019-03-13 10:10
CStone Pharmaceuticals listed on the Hong Kong Stock Exchange today 2019-02-27 10:47
1 2 3 4 5 6